Real Options For The Unvaccinated.
By Rick Hayes
The recent FDA-approved Pfizer Covid vaccine should be a good thing. But the tunnel-visioned, high-pressured push to mandate having millions of Americans vaccinated, even those with natural immunity, has only managed to escalate the suspicions of millions of people.
Freedom to choose what goes into one's body, a once fundamental choice in a free society, is no longer a guarantee. But more importantly, is the increasing distrust in a healthcare system charged with disseminating the truth as it pertains to available treatments.
Choosing to take the vaccine has now become a Hobson's choice. I.E., Americans are free to abstain from getting the injection but doing so will jeopardize their ability to earn a living and participate in society.
The question on the minds of millions of citizens and many doctors who fully support vaccination is why taking a vaccine has become a life and death decision when there are plenty of highly successful treatments available.
According to recent CDC figures, more than 595,000 people in the U.S. have died out of over 33 million cases of COVID-19. Hence the survival rate runs at approximately 98%. And the survival rate is reported to be higher using proven treatments.
Dr. Vladimir Zelenko, a family doctor from Monroe, New York, reported a 99.7% COVID survival rate for his patients. Zelenko said he applies a three-drug approach using Hydroxychloroquine, the antibiotic azithromycin, and Zinc Sulfate, with Zinc being the most crucial element.
Zinc is the "virus killer," said Zelenko, but adds that Zinc needs Hydroxychloroquine because it cannot enter the compromised cells without it. So, Hydroxychloroquine is used as a transporter that opens up channels that then allow Zinc to enter the cells and interfere with Covid-19 from replicating.
Zinc is a naturally occurring mineral sold OTC throughout the country in many pharmacies. Azithromycin is an FDA-approved antibiotic around since the early 1980s prescribed to treat infections of the lungs, sinuses, and other areas of the body. But what about Hydroxychloroquine?
Hydroxychloroquine is no stranger to the medical community. It has been around since it was first approved in 1955 by the FDA. Historically, it has enjoyed a reputation as generally safe and well-tolerated in patients treated for chronic inflammatory conditions. And for years, Hydroxychloroquine has been used to successfully treat autoimmune diseases such as lupus, rheumatoid arthritis and treat and prevent malaria. In 2005 Hydroxychloroquine was examined by Chinese doctors as a treatment of SARS-CoV-1.
The cost to treat patients with Hydroxychloroquine is certainly not a hindrance since the average treatment price runs approximately 20 dollars. In contrast, the drug Remdesivir, used to successfully treat Covid in hospital settings, costs insurance companies over $3,000 per patient.
More importantly, Zelenko emphasized the need to keep patients out of the hospital by following the specific protocol, which starts with treating patients early on an outpatient basis.
Zelenko stated that he treats patients within the first five days of clinical diagnosis, even before any test results are received.
"COVID-19 becomes a different disease once the patient is in the hospital setting," stated Dr. Harvey Risch, a distinguished cancer epidemiologist at the Yale School of Public Health. The overwhelming success of managing Covid 19 with Hydroxychloroquine comes from treatments made early and on an outpatient basis. After eight to ten days, the disease progresses to where individuals are hospitalized with pneumonia which has a completely different set of treatment protocols and medication demands.
What about the bad press Hydroxychloroquine has received over the past 18 months? And the fact that the FDA stopped its use to treat Covid-19?
Long before the pandemic, Hydroxychloroquine was considered so safe that it was sold as an OTC medication in France. In October 2019, several months before the world would learn of Covid-19, the French Ministry of Health office suddenly released a statement that Hydroxychloroquine was toxic and would require a prescription.
Dr. Didier Raoult, a French specialist in infectious diseases and one of the leading French researchers, determined that a trial involving 24 patients from southeast France showed Hydroxychloroquine and Azithromycin effectively treated Covid-19.
Raoult ultimately resigned from a committee investigating the pandemic in France because he observed Hydroxychloroquine suddenly being declared dangerous after being safely used for 80 years.
In the U.S., the FDA concluded that Hydroxychloroquine was unlikely to effectively treat COVID-19 for the authorized uses and cited serious cardiac adverse events. The FDA determined that the potential benefits of Hydroxychloroquine no longer outweigh the known and potential risks.
However, that determination was based on data collected in hospital settings where the patients were ill for periods outside the early time frame Zelenko stated was required for Hydroxychloroquine to be effective.
Risch also observed a disconnect between the successful early outpatient treatment of Covid patients using Hydroxychloroquine against the random FDA trials that were performed in hospital settings that concluded the treatments did not work.
As for the cardiac events mentioned by the FDA, Risch and Zelenko pointed out significant defects in the FDA's testing procedures that caused the cardiac events to be wrongfully attributed to Hydroxychloroquine.
Zelenko stated that he asked top electrophysiologists (Doctors who specialize in heart rhythm problems) if they had ever seen the cardiac issues mentioned by the FDA. According to Zelenko, electrophysiologists said they did not see any cardiac problems cited by the FDA in an outpatient setting. He added that the doctors saw some cardiac issues in the hospital settings, but it was unclear if Hydroxychloroquine or an already damaged heart from the virus was the cause.